<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pitt, Bertram</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">EMPHASIS-HF: An Analysis of the High-Risk Groups</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Recent results from the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure [EMPHASIS-HF] trial showed that eplerenone, compared with placebo, significantly reduced the risk of the composite of cardiovascular death and hospitalization for heart failure in patients with chronic systolic NYHA class II HF [NCT00232180; Zannad F et al. N Engl J Med 2011].</style></abstract><number><style face="normal" font="default" size="100%">10</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>